What Eli Lilly, Novo Nordisk earnings reveal about the future of GLP-1 sales

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 29 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 36%
  • Publisher: 63%

Novo Nordisk اخبار

Eli Lilly,Weight Loss,Weight-Loss Drug

GLP-1s continue to fuel investor interest in market competition, as companies prepare to differentiate themselves in the coming year.

missed second quarter Wall Street estimatesfor its GLP-1 sales. It beat Wall Street quarterly sales projections by 13% — with total sales of $4.3 billion for weight-loss drug Zepbound and diabetes drug Mounjaro. The stock surged more than 10% on Thursday as a result of Lilly signaling the easing of supply constraints helped Novo too. Its stock rose 5% that day.

Which is why some say market moves based on quarterly results in the near term isn't a good strategy. PARIS — Three German swimmers became ill after competing in the open water races at the Paris Olympics, though it was not immediately clear if the long-polluted Seine River was responsible for their sickness.

Jimmy Fallon has worked with Steph Curry before, so maybe it was easy for the superstar who delivered an all-timer of a performance for Olympic gold to pose for the Tonight Show host in the middle of a game. Because that's exactly what happened.

این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:

 /  🏆 47. in İR
 

از نظر شما متشکرم. نظر شما پس از بررسی منتشر خواهد شد.

ایران آخرین اخبار, ایران سرفصلها

Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.

Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsShares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The...
منبع: YahooFinanceCA - 🏆 47. / 63 ادامه مطلب »

What Eli Lilly, Novo Nordisk earnings show about GLP-1 salesRecent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created...
منبع: YahooFinanceCA - 🏆 47. / 63 ادامه مطلب »